Your browser is no longer supported. Please, upgrade your browser.
Settings
CTSO Cytosorbents Corporation daily Stock Chart
CTSO [NASD]
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.48 Insider Own4.70% Shs Outstand28.48M Perf Week3.64%
Market Cap324.67M Forward P/E- EPS next Y-0.38 Insider Trans-9.32% Shs Float25.41M Perf Month-3.80%
Income-14.00M PEG- EPS next Q-0.14 Inst Own15.40% Short Float9.47% Perf Quarter13.43%
Sales19.20M P/S16.91 EPS this Y31.10% Inst Trans17.02% Short Ratio6.85 Perf Half Y57.79%
Book/sh0.71 P/B16.06 EPS next Y33.30% ROA-51.10% Target Price16.13 Perf Year137.50%
Cash/sh0.89 P/C12.83 EPS next 5Y- ROE-100.50% 52W Range4.65 - 13.40 Perf YTD75.38%
Dividend- P/FCF- EPS past 5Y16.40% ROI-45.20% 52W High-14.93% Beta0.05
Dividend %- Quick Ratio8.60 Sales past 5Y62.40% Gross Margin68.00% 52W Low145.16% ATR0.56
Employees101 Current Ratio8.80 Sales Q/Q61.10% Oper. Margin-69.40% RSI (14)47.31 Volatility5.11% 5.03%
OptionableYes Debt/Eq0.46 EPS Q/Q-209.60% Profit Margin-73.10% Rel Volume0.63 Prev Close11.00
ShortableYes LT Debt/Eq0.46 EarningsAug 02 AMC Payout- Avg Volume351.12K Price11.40
Recom2.00 SMA20-3.02% SMA50-2.39% SMA20032.29% Volume220,946 Change3.64%
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
Aug-08-18 12:30PM  CTSO: Q2 Product Sales Beat Big. New Catalysts Come Online. Moving PT to $15/share Zacks Small Cap Research
08:10AM  Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-03-18 01:24PM  Edited Transcript of CTSO earnings conference call or presentation 2-Aug-18 8:45pm GMT Thomson Reuters StreetEvents -9.88%
05:09AM  CytoSorbents: 2Q Earnings Snapshot Associated Press
Aug-02-18 04:15PM  CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018 PR Newswire
02:45PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Jul-31-18 07:08AM  CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide PR Newswire
Jul-26-18 07:00AM  CytoSorbents to Report Q2 2018 Operating and Financial Results PR Newswire
Jul-09-18 08:00AM  Aferetica and CytoSorbents Debut the PerLife System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society PR Newswire +6.52%
Jun-26-18 07:08AM  CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes PR Newswire
Jun-12-18 07:08AM  CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility PR Newswire
Jun-04-18 07:30AM  CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-21-18 09:26AM  CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference PR Newswire
May-14-18 07:08AM  CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use PR Newswire
May-09-18 05:40PM  CTSO: Q1 2018 Update: Product Sales New Record. REFRESH 2 Enrollment Should Pick Up Steam. REMOVE Already Ramping Zacks Small Cap Research
May-08-18 06:27PM  CytoSorbents: 1Q Earnings Snapshot Associated Press
04:15PM  CytoSorbents Reports Strong First Quarter 2018 Financial Results PR Newswire
May-07-18 09:47AM  What You Must Know About Cytosorbents Corporations (NASDAQ:CTSO) Financial Strength Simply Wall St.
May-04-18 07:40AM  New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security, Washington Real Estate Investment Trust, and CPB Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-02-18 07:00AM  CytoSorbents to Report Q1 2018 Operating and Financial Results PR Newswire
Apr-24-18 07:08AM  CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery PR Newswire
Apr-09-18 01:57AM  CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich PR Newswire
Apr-04-18 06:55AM  CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank PR Newswire
Mar-28-18 09:17AM  CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference PR Newswire
Mar-19-18 10:15AM  CTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study Underway Zacks Small Cap Research
07:45AM  Research Report Identifies Matrix Service, Barrett Business Services, Materion, C&J Energy Services, YRC Worldwide, and Cytosorbents with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-12-18 07:00AM  CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference PR Newswire
Mar-08-18 04:15PM  CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017 PR Newswire
01:30PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Mar-01-18 08:00AM  CytoSorbents to Report Fiscal 2017 Operating and Financial Results PR Newswire
Feb-26-18 07:10AM  CytoSorbents to Participate at the BTIG Healthcare Conference PR Newswire
Feb-15-18 06:55AM  CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia PR Newswire
Feb-13-18 05:10PM  CytoSorbents' CEO on flu epidemic Yahoo Finance Video
Feb-06-18 07:08AM  CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference PR Newswire
Feb-01-18 07:20AM  New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification PR Newswire
Jan-12-18 11:45AM  CTSO: Q4 Preannouncement, Our Initial Thoughts on REFRESH II Zacks Small Cap Research
Jan-09-18 08:10AM  New Research: Key Drivers of Growth for Merit Medical, NETGEAR, Hancock Holding, Alexandria Real Estate Equities, Cytosorbents, and Stepan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-08-18 07:15AM  CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter PR Newswire +6.38%
Jan-03-18 07:05AM  CytoSorbents To Provide Corporate Update at Biotech Showcase 2018 PR Newswire
Jan-01-18 09:13AM  CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-28-17 08:45AM  Streetwise Reports Examines an Immunotherapy Firm That Received a Green Light from FDA for Pivotal Trial GlobeNewswire
Dec-21-17 02:58PM  CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application PR Newswire +6.50%
Dec-19-17 02:00PM  CTSO: Large Infective Endocarditis Clinical Study Could Be Win-Win for CytoSorbents Zacks Small Cap Research
07:00AM  CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program PR Newswire
Dec-11-17 08:10AM  German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial PR Newswire
Dec-08-17 12:36PM  ETFs with exposure to CytoSorbents Corp. : December 8, 2017 Capital Cube
Nov-29-17 07:00AM  CytoSorbents to Present at the LD Micro Main Event Investor Conference PR Newswire
Nov-23-17 06:31PM  Is Cytosorbents Corporations (CTSO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-21-17 11:00AM  CTSO: Germany Reimbursement Rebounds, Drives Strong Record Product Zacks Small Cap Research
Nov-09-17 06:25PM  CytoSorbents reports 3Q loss Associated Press
04:17PM  CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 PR Newswire
12:50PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
12:29PM  ETFs with exposure to CytoSorbents Corp. : November 9, 2017 Capital Cube
07:15AM  CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500 as One of the Fastest Growing Companies in North America PR Newswire
Nov-02-17 08:00AM  CytoSorbents to Report Q3 2017 Operating and Financial Results PR Newswire
Nov-01-17 07:05AM  CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia PR Newswire
Oct-30-17 11:38AM  ETFs with exposure to CytoSorbents Corp. : October 30, 2017 Capital Cube
Oct-27-17 09:00AM  CTSO: Additional Evidence Supporting CytoSorb Use in Sepsis, Cardiac Surgery Zacks Small Cap Research
Oct-20-17 10:09AM  ETFs with exposure to CytoSorbents Corp. : October 20, 2017 Capital Cube
Oct-19-17 09:25AM  CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival PR Newswire
Oct-10-17 07:15AM  CytoSorbents to Present at the 2017 BIO Investor Forum PR Newswire
Oct-09-17 11:26AM  ETFs with exposure to CytoSorbents Corp. : October 9, 2017 Capital Cube
Oct-06-17 09:10AM  CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube -5.38%
Sep-26-17 07:05AM  CytoSorbents Introduces the CytoSorb Therapeutic ECMO Kit at the 2017 European Society of Intensive Care Medicine Congress PR Newswire
Sep-25-17 07:15AM  Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb® PR Newswire
Sep-14-17 08:15AM  World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony PR Newswire -8.62%
Sep-11-17 07:15AM  Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation PR Newswire
Sep-06-17 07:00AM  CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference PR Newswire
Sep-05-17 08:05AM  CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium PR Newswire +11.54%
Aug-14-17 10:00AM  CTSO: Product Revenue Sets New Record, Further Growth Expected in 2H Zacks Small Cap Research
07:15AM  CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients PR Newswire
Aug-07-17 04:15PM  CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 PR Newswire
10:30AM  Investor Network: CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Aug-02-17 07:00AM  Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® PR Newswire
Aug-01-17 07:00AM  CytoSorbents to Report Q2 2017 Operating and Financial Results PR Newswire
Jul-17-17 09:15AM  CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR PR Newswire
Jul-13-17 07:05AM  CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma PR Newswire
Jul-05-17 07:05AM  CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank PR Newswire
Jun-15-17 07:05AM  CytoSorbents Announces Director and Management Open Market Stock Purchases PR Newswire +7.25%
Jun-06-17 09:48AM  CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors PR Newswire
May-30-17 07:15AM  Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer PR Newswire
May-24-17 08:05AM  CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference PR Newswire
May-22-17 01:32PM  ETFs with exposure to CytoSorbents Corp. : May 22, 2017 Capital Cube
09:00AM  Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021 PR Newswire
May-15-17 04:00PM  CTSO: Revenue Acceleration Expected 2H. REFRESH Efficacy Compelling Zacks Small Cap Research
May-10-17 11:16AM  CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-09-17 04:30PM  ETFs with exposure to CytoSorbents Corp. : May 9, 2017 Capital Cube
May-08-17 05:23PM  CytoSorbents reports 1Q loss Associated Press
04:30PM  CytoSorbents Reports First Quarter 2017 Financial Results PR Newswire
11:10AM  Investor Network: CytoSorbents Corporation to Host Earnings Call Accesswire
May-05-17 09:00AM  CytoSorbents Announces Positive REFRESH I Trial Results PR Newswire
May-02-17 07:00AM  CytoSorbents to Report Q1 2017 Operating and Financial Results PR Newswire
Apr-24-17 08:00AM  CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification PR Newswire
Apr-19-17 08:30AM  CytoSorbents 2017 - Propelling the Company to the "Next Level" PR Newswire
Apr-17-17 09:00AM  CTSO: Equity Raise, Cancer Applications, REFRESH I Data Upcoming Zacks Small Cap Research
Apr-05-17 04:35PM  ETFs with exposure to CytoSorbents Corp. : April 5, 2017 Capital Cube
Apr-03-17 05:03PM  CYTOSORBENTS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-31-17 08:00AM  CytoSorbents Announces Pricing of Follow-On Offering PR Newswire -17.43%
Mar-30-17 04:01PM  CytoSorbents Announces Proposed Offering of Common Stock PR Newswire
Mar-28-17 07:15AM  CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia PR Newswire
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Capponi VincentChief Operating OfficerAug 03Option Exercise3.457,60026,220340,368Aug 06 05:21 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 03Option Exercise2.8810,00028,750260,004Aug 07 03:18 PM
Capponi VincentChief Operating OfficerAug 03Sale13.087,60099,408332,768Aug 06 05:21 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 03Sale12.5410,000125,364250,004Aug 07 03:18 PM
Capponi VincentChief Operating OfficerAug 02Option Exercise3.452,8359,781335,603Aug 06 05:21 PM
Capponi VincentChief Operating OfficerAug 02Sale13.002,83536,855332,768Aug 06 05:21 PM
Capponi VincentChief Operating OfficerJun 15Option Exercise1.3948,63367,374367,983Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 15Sale12.008,633103,596347,983Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 14Option Exercise3.7511,36742,626319,350Jun 18 06:14 PM
Capponi VincentChief Operating OfficerJun 14Sale12.0011,367136,404356,616Jun 18 06:14 PM
Capponi VincentChief Operating OfficerMay 17Option Exercise1.8328,00051,100345,551May 18 02:47 PM
Capponi VincentChief Operating OfficerMay 17Sale10.0028,000280,000317,551May 18 02:47 PM
Capponi VincentChief Operating OfficerMay 16Option Exercise0.884,8464,240322,397May 18 02:45 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 16Option Exercise4.6912,40058,156265,704May 16 09:32 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 16Sale9.0012,400111,600253,304May 16 09:32 PM
Capponi VincentChief Operating OfficerMay 16Sale9.004,84643,614317,551May 18 02:45 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 15Option Exercise4.6912,40058,156265,704May 16 09:31 PM
Capponi VincentChief Operating OfficerMay 15Option Exercise2.737,15419,560324,705May 17 12:53 PM
Capponi VincentChief Operating OfficerMay 15Sale9.007,15464,386317,551May 17 12:53 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 15Sale8.7512,400108,500253,304May 16 09:31 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 14Option Exercise2.9010,00029,000263,304May 16 02:01 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 14Sale8.5010,00085,000253,304May 16 02:01 PM
BLOCH KATHLEEN P.Chief Financial OfficerApr 17Option Exercise4.69120563253,424Apr 18 09:35 PM
BLOCH KATHLEEN P.Chief Financial OfficerApr 17Sale8.25120990253,304Apr 18 09:35 PM
BLOCH KATHLEEN P.Chief Financial OfficerMar 15Option Exercise4.6911,17652,415261,246Mar 19 10:18 AM
BLOCH KATHLEEN P.Chief Financial OfficerMar 15Sale8.2511,17692,202250,070Mar 19 10:18 AM
BLOCH KATHLEEN P.Chief Financial OfficerMar 13Option Exercise4.691,1045,178251,174Mar 15 01:28 PM
BLOCH KATHLEEN P.Chief Financial OfficerMar 13Sale8.251,1049,108250,070Mar 15 01:28 PM
BLOCH KATHLEEN P.Chief Financial OfficerFeb 21Option Exercise2.9010,00029,000268,870Apr 05 07:14 PM
BLOCH KATHLEEN P.Chief Financial OfficerFeb 21Sale8.0010,00080,000258,870Apr 05 07:14 PM
Capponi VincentChief Operating OfficerJan 16Option Exercise6.2544,000275,000319,062Jan 18 05:23 PM
BLOCH KATHLEEN P.Chief Financial OfficerJan 12Option Exercise4.6912,40058,156241,038Jan 17 07:59 PM
BLOCH KATHLEEN P.Chief Financial OfficerJan 12Sale7.7512,40096,100228,638Jan 17 07:59 PM
BLOCH KATHLEEN P.Chief Financial OfficerJan 08Option Exercise3.5932,400116,156261,038Jan 10 09:50 PM
BLOCH KATHLEEN P.Chief Financial OfficerJan 08Sale7.3032,400236,400228,638Jan 10 09:50 PM
Capponi VincentChief Operating OfficerNov 27Option Exercise4.204,00016,800275,062Dec 08 04:12 PM
Capponi VincentChief Operating OfficerNov 27Sale7.004,00028,000271,062Dec 08 04:12 PM